Open access · CC-BY
via OpenAlex
APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis
Leslie A. Crews, Edward M. Rockenstein, Eliezer Masliah
Brain Structure and Function · 2009 · ▲ 106 citations
Abstract
Neurodegenerative disorders of the aging population affect over 5 million people in the US and Europe alone. The common feature is the progressive accumulation of misfolded proteins with the formation of toxic oligomers. Alzheimer's disease (AD) is characterized by cognitive impairment, progressive degeneration of neuronal populations in the neocortex and limbic system, and formation of amyloid plaques and neurofibrillary tangles. Amyloid-beta (Abeta) is the product of proteolysis of amyloid precursor protein (APP) by beta and gamma-secretase enzymes. The neurodegenerative process in AD initiates with axonal and synaptic damage and is associated with progressive accumulation of toxic Abeta oligomers in the intracellular and extracellular space. In addition, neurodegeneration in AD is associated with alterations in neurogenesis. Abeta accumulation is the consequence of an altered balance between protein synthesis, aggregation rate, and clearance. Identification of genetic mutations in APP associated with familial forms of AD and gene polymorphisms associated with the more common sporadic variants of AD has led to the development of transgenic (tg) and knock out rodents as well as viral vector driven models of AD. While APP tg murine models with mutations in the N- and C-terminal flanking regions of Abeta are characterized by increased Abeta production with plaque formation, mutations in the mid-segment of Abeta result in increased formation of oligomers, and mutations toward the C-terminus (E22Q) segment results in amyloid angiopathy. Similar to AD, in APP tg models bearing familial mutations, formation of Abeta oligomers results in defective plasticity in the perforant pathway, selective neuronal degeneration, and alterations in neurogenesis. Promising results have been obtained utilizing APP tg models of AD to develop therapies including the use of beta- and gamma-secretase inhibitors, immunization, and stimulating neurogenesis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s00429-009-0232-6
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Crews, L., Rockenstein, E.M., & Masliah, E. (2009). APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis. <em>Brain Structure and Function</em>. https://doi.org/10.1007/s00429-009-0232-6
Vancouver
Crews L, Rockenstein EM, Masliah E. APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Structure and Function. 2009. doi:10.1007/s00429-009-0232-6.
BibTeX
@article{lesliea2009APPtra,
title = {APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis},
author = {Leslie A. Crews and Edward M. Rockenstein and Eliezer Masliah},
journal = {Brain Structure and Function},
year = {2009},
doi = {10.1007/s00429-009-0232-6},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Molecular Genetics 2010
Open access · OA
Molecular mechanisms of neurodegeneration in Alzheimer's disease
FEBS Journal 2010
Open access · OA
Amyloid oligomers: formation and toxicity of Aβ oligomers
The FASEB Journal 2000
Citation only
Protein aging hypothesis of Alzheimer disease
PubMed 2020
Preprint
[Adult neurogenesis: alterations with aging and Alzheimer's disease development.]
Molecules and Cells 2017
Open access · CC-BY
Molecular and Cellular Basis of Neurodegeneration in Alzheimer’s Disease
PLoS ONE 2008
Open access · CC0